文献速递前列腺增生与排尿功能障碍

持续抗栓治疗下BPH内镜手术围手术期结局的系统综述与荟萃分析

Perioperative outcomes of ongoing antithrombotic therapy during endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of observational studies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-03-05

结果显示PVP在持续抗栓治疗下输血、止血及泌尿系并发症发生率相当,而TURP和剜除术出血相关并发症显著增加,尤其抗凝亚组。

要点

  • 持续抗栓治疗下PVP的围手术期结局与未抗栓患者相当,安全性较好。
  • TURP和剜除术在持续抗栓治疗下出血相关并发症显著增加,抗凝亚组风险更高。
  • 剜除术抗栓用户还需关注需手术止血的出血和急性尿潴留风险升高。

核心结论

  • 持续抗栓治疗下PVP围手术期结局与未抗栓患者相当,可能为需不间断抗栓治疗高危患者的首选术式。
  • 持续抗栓治疗尤其抗凝显著增加TURP和剜除术后出血风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Medline、Embase和Scopus数据库至2025年9月17日。
  • 采用随机效应模型合并均数差或比值比及95%置信区间。

主要发现

  • 手术时间、术后血红蛋白下降、导尿时间和持续膀胱冲洗时间在各术式两组间相当。
  • TURP抗栓组出血相关并发症显著增加(OR 1.90,95%CI 1.05-3.41,p=0.03)。
  • 剜除术抗栓组出血相关并发症显著增加(OR 2.91,95%CI 1.71-4.93,p<0.0001),抗凝亚组OR 4.80(p=0.0002)。
  • 剜除术抗栓组需手术止血的出血风险升高(OR 3.69,95%CI 1.73-7.84,p=0.0007),急性尿潴留风险升高(OR 1.36,95%CI 1.04-1.77,p=0.02)。
  • PVP组输血、止血及泌尿系并发症发生率在抗栓与否间相当;TURP和PVP抗栓组住院时间略长(p<0.05)。

临床怎么用

  • 需不间断抗栓治疗的高危BPH患者可优先考虑PVP。
  • 持续抗栓治疗下选择TURP或剜除术应警惕出血风险,尤其抗凝患者。
  • 临床决策应个体化平衡血栓栓塞风险与预期出血风险,必要时多学科协作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of antithrombotic therapy in patients undergoing endoscopic surgery for benign prostatic hyperplasia (BPH) remains challenging due to competing risks of thromboembolism and perioperative bleeding. This meta-analysis evaluated perioperative outcomes among patients undergoing endoscopic prostate procedures while continuing antiplatelet (APT) or anticoagulant (AC) therapy compared with patients not receiving antithrombotic treatment. METHODS: Literature search was conducted on 17th September 2025 including PubMed, Medline, Embase, and Scopus database, to identify comparative studies evaluating perioperative outcomes of endoscopic prostate procedures in patients on versus off APT/AC therapy were identified. Data were pooled using random-effects models to estimate mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Fifteen studies comprising 6091 patients (1900 on APT/AC, 4191 controls) were included. Operative time, postoperative hemoglobin decrease, catheterization duration, and continuous bladder irrigation time were comparable between groups across all surgical modalities. However, bleeding-related complications were significantly more frequent among APT/AC users undergoing transurethral resection of the prostate (TURP) (OR 1.90, 95% CI 1.05-3.41, p = 0.03) and enucleation (OR 2.91, 95% CI 1.71-4.93, p < 0.0001), particularly in the AC subgroup (OR 4.80, p = 0.0002). Enucleation also carried higher odds of bleeding requiring surgical hemostasis (OR 3.69, 95% CI 1.73-7.84, p = 0.0007) and acute urinary retention (OR 1.36, 95% CI 1.04-1.77, p = 0.02) among antithrombotic users. Conversely, photoselective vaporization (PVP) demonstrated comparable rates of transfusion, hemostasis, and urinary complications regardless of APT/AC therapy. Hospital stay was marginally longer after TURP and PVP among APT/AC users (p < 0.05). CONCLUSIONS: Continuation of antithrombotic therapy during PVP appears safe, with perioperative outcomes comparable to those of non-antithrombotic patients. Conversely, its ongoing use-especially AC-significantly increases bleeding risks following TURP and enucleation. PVP may therefore represent the preferred modality for high-risk patients requiring uninterrupted antithrombotic therapy. Clinical decision-making should balance individual thromboembolic risk against anticipated bleeding risk, with multidisciplinary input when appropriate.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Giulioni C, Cafarelli A, Falsetti F, et al. Perioperative outcomes of ongoing antithrombotic therapy during endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2026. PMID: 41781484. doi:10.1038/s41391-026-01098-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。